secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001493152-24-019097
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma Q1 update: FDA clears Phase 2 glioblastoma trial; cash $4.2M
---------------------------------------------------------------------------

- FDA approved Phase 2 trial of Ropidoxuridine for glioblastoma; central IRB approved; first patient dosing expected Q2 2024.
- Cash and marketable securities at March 31, 2024 totaled approx. $4.2 million.
- Formed new wholly owned subsidiary Shuttle Diagnostics to develop predictive biomarker tests for prostate cancer.
- Obtained exclusive licenses from Georgetown University for predictive biomarker program and PSMA-B IP for metastatic prostate cancer.
- Finalizing site enrollment at up to six institutions for Phase 2 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/0001493152-24-019097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224019097/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer